Pieris Pharmaceuticals Inc (NASDAQ: PIRS) stock closed at $23.59 on 4/1/25 after a major decline of -15.7%. Moreover, above average trading volume at 142% of normal accompanied the decline. The stock has declined -15.4% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Pieris Pharmaceuticals has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Pieris Pharmaceuticals has a very low Appreciation Score of 0 but a very high Power Rating of 88, resulting in the Low Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment